Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study (vol 15, pg 954, 2014)

被引：0
|
作者：
Ribas, A.
Gonzalez, R.
Pavlick, A.
机构：
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E417 / E417
页数：1
相关论文
共 50 条
  • [1] Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
    Ribas, Antoni
    Gonzalez, Rene
    Pavlick, Anna
    Hamid, Omid
    Gajewski, Thomas F.
    Daud, Adil
    Flaherty, Lawrence
    Logan, Theodore
    Chmielowski, Bartosz
    Lewis, Karl
    Kee, Damien
    Boasberg, Peter
    Yin, Ming
    Chan, Iris
    Musib, Luna
    Choong, Nicholas
    Puzanov, Igor
    McArthur, Grant A.
    [J]. LANCET ONCOLOGY, 2014, 15 (09): : 954 - 965
  • [2] TERT promoter mutations in patients with BRAFV600-mutated melanoma treated with vemurafenib or cobimetinib combined with vemurafenib
    Wongchenko, M. J.
    Larkin, J.
    Mcarthur, G. A.
    Ribas, A.
    Dreno, B.
    Chapman, P. B.
    Maio, M.
    Garbe, C.
    Robert, C.
    Lu, W.
    Diala, I.
    Darbonne, W. C.
    Chang, I.
    Hsu, J. J.
    Caro, I.
    Rooney, I.
    Ascierto, P. A.
    Yan, Y.
    [J]. MELANOMA RESEARCH, 2016, 26 : E40 - E41
  • [3] Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study
    Wongchenko, Matthew J.
    Ribas, Antoni
    Ascierto, Paolo A.
    Dreno, Brigitte
    di Giacomo, Anna Maria
    Garbe, Claus
    Chang, Ilsung
    Hsu, Essie
    Rooney, Isabelle
    Lu, William
    Koeppen, Hartmut
    Larkin, James
    Yan, Yibing
    McArthur, Grant A.
    [J]. JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 18
  • [4] An imaging study of vemurafenib in patients with BRAFV600-mutated metastatic melanoma.
    Lastoria, Secondo
    Grimaldi, Antonio M.
    Aloj, Luigi
    Simeone, Ester
    Romano, Anna
    Caraco, Corradina
    Curvietto, Marcello
    Esposito, Assunta
    Caraco, Corrado
    Mozzillo, Nicola
    Torri, Valter
    Ascierto, Paolo Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAFV600-mutated Metastatic Melanoma
    Yan, Yibing
    Wongchenko, Matthew J.
    Robert, Caroline
    Larkin, James
    Ascierto, Paolo A.
    Dreno, Brigitte
    Maio, Michele
    Garbe, Claus
    Chapman, Paul B.
    Sosman, Jeffrey A.
    Shi, Zhen
    Koeppen, Hartmut
    Hsu, Jessie J.
    Chang, Ilsung
    Caro, Ivor
    Rooney, Isabelle
    McArthur, Grant A.
    Ribas, Antoni
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (11) : 3239 - 3246
  • [6] CONVERCE: evaluation of cobimetinib and vemurafenib combination treatment in patients with brain metastases from BRAFV600 mutated melanoma
    Lesimple, T.
    Campillo-Gimenez, B.
    Leccia, M. T.
    Mahmoudi, A.
    Lebbe, C.
    [J]. MELANOMA RESEARCH, 2016, 26 : E47 - E48
  • [7] CONVERCE: evaluation of cobimetinib and vemurafenib combination treatment in patients with brain metastases from BRAFV600 mutated melanoma
    Lesimple, T.
    Campillo-Gimenez, B.
    Leccia, M. T.
    Mahmoudi, A.
    Lebbe, C.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib plus vemurafenib or vemurafenib alone
    Yan, Y.
    Robert, C.
    Larkin, J.
    Ascierto, P. A.
    Dreno, B.
    Maio, M.
    Garbe, C.
    Chapman, P. B.
    Sosman, J. A.
    Wongchenko, M. J.
    Hsu, J. J.
    Chang, I.
    Caro, I.
    Rooney, I.
    McArthur, G.
    Ribas, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [9] Vemurafenib (VEM) and MEK inhibitor, cobimetinib (GDC-0973), in advanced BRAFV600-mutated melanoma (BRIM7): dose-escalation and expansion results of a phase IB study
    McArthur, G.
    Gonzalez, R.
    Pavlick, A.
    Hamid, O.
    Puzanov, I.
    Gajewski, T. F.
    Daud, A.
    Yin, M.
    Choong, N.
    Ribas, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S856 - S857
  • [10] Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) plus vemurafenib (VEM) in the phase 3 coBRIM study
    McArthur, G.
    Larkin, J.
    Dreno, B.
    Ascierto, P.
    Liszkay, G.
    Maio, M.
    Mandala, M.
    Demidov, L.
    Stroyakovskiy, D.
    Thomas, L.
    De la Cruz-Merino, L.
    Atkinson, V.
    Dutriaux, C.
    Garbe, C.
    Wongchenko, M.
    Hsu, J.
    Koralek, D.
    Rooney, I.
    Yan, Y.
    Ribas, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S722 - S723
12345